Revolution Medicines, Inc.

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

RVMD$193.06-3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Operating expenses:
Research and development	$262,506	$151,752	$692,389	$404,129
General and administrative	52,763	23,960	128,354	69,085
Total operating expenses	315,269	175,712	820,743	473,214
Loss from operations	(315,269)	(175,712)	(820,743)	(473,214)
Non-operating income (expense):
Interest income	22,083	20,411	69,402	65,658
Interest expense	(11,428)	—	(12,295)	—
Change in fair value of warrant liabilities and contingent earn-out shares	(592)	(1,269)	(2,731)	4,543
Other income (expense), net	—	282	(42)	(2,511)
Total non-operating income, net	10,063	19,424	54,334	67,690
Loss before income taxes	(305,206)	(156,288)	(766,409)	(405,524)
Net loss	$(305,206)	$(156,288)	$(766,409)	$(405,524)
Net loss per share attributable to common stockholders, basic and diluted	$(1.61)	$(0.94)	$(4.06)	$(2.45)
Weighted-average common shares used to compute net loss per share, basic and diluted	189,231,562	166,843,984	188,657,560	165,576,333
Comprehensive loss:
Net loss	$(305,206)	$(156,288)	$(766,409)	$(405,524)
Other comprehensive gain:
Unrealized gain on investments, net	1,814	5,675	1,795	3,268
Comprehensive loss	$(303,392)	$(150,613)	$(764,614)	$(402,256)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.